Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL

Slideset - In a subanalysis of a phase II trial, patients with R/R B-precursor ALL after alloHSCT achieved a 45% CR/CRh rate with blinatumomab treatment.

Source: Clinical Care Options Leukemia - December 14, 2015 Category: Hematology Source Type: research